Objective:To study the effect and mechanism of Supplemental Sini San(SNSJW) on rats liver hepatic fibrosis. Method: The immunohepatic fibrosis model was induced by intraperitoneal injection of porcine serum.in to rats.Seventy Wister rats were divided into seven groups:normol control

model control

SNSJW high-dose group

mediate-dose group and low-dose group

prevention group

Sini San(SNS) group. Except the normol control groups

all the other groups were injected with pig's serum without inactivation into abdominal cavity

twice per week and 0.5 mL each time

persisting for 10 weeks. The prevention groups were injected the stomach with the medicines(SNSJW 7 g·kg-1

10 weeks)at the same time when models began to be made

the other treatment groups were dealed with just as the prevention groups 6 weeks later persisting for 4 weeks. Ten rats were randomly taken for decollation in all six groups at the end of 10th week.SNS group 4 g·kg-1

SNSJW high-dose group 14 g·kg-1

mediate-dose group 7 g·kg-1

low-dose group 3.5 g·kg-1.The changes of hepatic fibrosiswere detected respectively.The expression of transforming growth factor-β1(TGF-β1)

p38motogen-activated protein kinase(p38MAPK)

a-smooth muscle actin(α-SMA)

matrixmetalloproteinase-13 (MMP-13)

and tissue inhibitive factor of metalloprote-ase(TIMP-1) in liver tissue were detected by immunohistochemical techniques. Result: Compared with SNSJW mediate-dose group with model group

the expression of TGF-β1

p38MAPK

α-SMA and TIMP-1 protein was lower

but the expression of MMP-13 protein was significantly higher in SNSJW mediate-dose group. Conclusion: Supplemental Sini San has a positive action of treatment on hepatic fibrosis model rats

the mechanism is related with its inhibiting the expression of TGF-β1

TIMP-1 protein and enhancing MMP-13 in rats.